Clinical trials
Oligodendroglioma clinical trials
Below are recruiting oligodendroglioma clinical trials, each written for real people, not researchers. We’re tracking 21 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04702581RecruitingPhase 3
Delayed radiation versus usual timing for certain brain tumors
This trial studies whether delaying radiation therapy helps people with a slow-growing brain tumor called low-grade oligodendroglioma that has specific genetic markers. It compares delayed radiation to standard timing to see which approach controls the tumor with acceptable side effects and quality of life.
AmiensAges 18 years+ - NCT06254326RecruitingPhase 1
Immune cell therapy for recurrent oligodendroglioma
This trial tests a personalized immune cell therapy for adults with a specific type of brain tumor (oligodendroglioma) that has come back. The treatment uses your own immune cells to target the tumor.
Gainesville, FloridaAges 18–89 - NCT05303519RecruitingPhase 3
Safusidenib for IDH1-mutant glioma after main treatment
This Phase 3 trial tests safusidenib, a targeted medicine, to help stop or slow the return of certain brain tumors with an IDH1 mutation. It focuses on people after initial treatment (surgery and/or radiation and temozolomide), aiming to improve outcomes during maintenance therapy.
Birmingham, AlabamaAges 18 years+ - NCT07286292RecruitingPhase 2
Vorasidenib for children with IDH-mutated low-grade glioma
This trial studies an oral drug called vorasidenib for children and teens with a slow-growing brain tumor (Grade 2 astrocytoma or oligodendroglioma) that has an IDH1 or IDH2 mutation. The drug is taken daily and may help keep the tumor from growing, avoiding the need for immediate chemotherapy or radiation.
SydneyAges 12–17 - NCT04135807RecruitingEarly Phase 1
Implantable device test for operable brain tumor patients
This early-phase trial tests a tiny implanted device placed during brain tumor surgery. It delivers very small doses of medicine directly to the tumor area for a short time, aiming to see if this approach is safe and workable in patients with certain gliomas.
Boston, MassachusettsAges 18 years+ - NCT04541082RecruitingPhase 1
Oral ONC206 for recurrent brain and spinal tumors
This early-phase study tests an oral medicine called ONC206 in adults with recurrent, rare brain or spinal cord tumors. The goal is to find a safe dose and look for signs the treatment can shrink or control the cancer.
Bethesda, MarylandAges 18 years+ - NCT04623931RecruitingPhase 2
Chemo and radiation for IDH-wildtype glioma
This Phase 2 study tests a combination of chemotherapy and radiation after surgery for certain brain tumors that are “IDH wildtype.” It aims to control the tumor and improve outcomes for people with specific types of glioma or glioblastoma.
Houston, TexasAges 18 years+ - NCT05190172Recruiting
Proton versus photon radiation for IDH-mutated brain tumors
This trial compares two types of radiation—proton therapy versus photon (standard) therapy—for adults with an IDH-mutated grade 2 or 3 brain tumor. The goal is to see which approach works better and/or causes fewer side effects while treating the tumor.
OsloAges 18–65 - NCT05512351RecruitingPhase 2
Immunotherapy plus low-dose Avastin for recurrent oligodendroglioma
This Phase 2 trial tests an immune treatment (sintilimab, an anti–PD-1 antibody) together with low-dose bevacizumab (Avastin) to treat oligodendroglioma that has come back, including cases detected by tumor DNA in body fluid. It aims to slow or control tumor growth and help reduce symptoms by targeting both the tumor and its blood supply.
Zhengzhou, HenanAges 18 years+ - NCT04648462Recruiting
Proton therapy planning for certain brain tumors
This study builds and tests how proton therapy planning could better protect the brain compared with standard radiation (photon therapy) for adults with certain brain tumors. It may help reduce radiation to sensitive areas like the hippocampus, with the goal of better long-term brain function.
Maastricht, LimburgAges 18 years+ - NCT05331521RecruitingPhase 3
Study to improve brain function in newly diagnosed glioma patients
This Phase 3 study tests a treatment plan after surgery to improve brain function and quality of life in adults with newly diagnosed, specific types of brain tumors (gliomas). It may help you keep thinking clearly and living better while your tumor is treated with standard medicines.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT05345002RecruitingPhase 2
ATRA plus PD-1 therapy for IDH-mutant recurrent brain tumors
This trial studies whether adding all-trans retinoic acid (ATRA) to an anti–PD-1 immune therapy can slow recurrent or worsening IDH-mutant glioma. It may help by boosting the immune system’s attack on the tumor.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05698524RecruitingPhase 1
Temodar plus an investigational pill for recurrent brain cancer
This Phase 1 study tests an investigational drug (PCI-24781) together with Temodar in people whose high-grade glioma (grade III/IV) has come back after prior treatment. It aims to find a safe dose and see how well the combination may work for recurrent disease.
Omaha, NebraskaAges 19 years+ - NCT05956821RecruitingPhase 1/Phase 2
Study drug for young people with recurring brain glioma
This Phase 1/2 trial tests a study treatment for children and young adults under 22 whose brain glioma has come back or isn’t responding to prior treatment. It’s designed to see whether the treatment is safe and effective for shrinking tumors in this situation.
Miami, FloridaAges 1–21 - NCT06161974RecruitingPhase 2
Olutasidenib and temozolomide for IDH1-mutant high-grade glioma
This trial tests a combination of two oral medications, olutasidenib and temozolomide, for people with a specific type of aggressive brain tumor (high-grade glioma) that has an IDH1 mutation. The goal is to see if this combination can help control the tumor after standard treatment like radiation.
Aurora, ColoradoAges 12–39 - NCT06930846Recruiting
Brain cancer cognitive training study
This study tests a home-based program called HOBSCOTCH-CA to help with memory and thinking problems after brain cancer treatment. The program uses phone and internet sessions to teach self-management skills.
Lebanon, New HampshireAges 18 years+ - NCT06989086Recruiting
FearLess support for brain tumor patients and caregivers
This study tests a program to help people with brain tumors and their caregivers manage fear of recurrence. You would attend virtual sessions to learn coping skills.
Richmond, VirginiaAges 18 years+ - NCT07159607Recruiting
PET scan for IDH-mutant brain tumors
This trial uses a special PET scan to see how IDH-mutant gliomas respond to treatment. It may help your doctor better track your tumor's activity.
ViennaAges 18 years+ - NCT01649830RecruitingPhase 3
Temozolomide after radiation for low-grade brain tumor
This trial tests whether adding temozolomide chemotherapy after radiation helps control a type of low-grade brain tumor that was not fully removed. It may help reduce the chance the tumor comes back, compared with standard post-radiation care.
Guangzhou, GuangdongAges 18–60 - NCT07468136RecruitingPhase 1/Phase 2
Retifanlimab with or without DFMO for progressive high-grade gliomas
This study tests a combination of two drugs—retifanlimab (an immunotherapy that helps your immune system fight cancer) and DFMO (a medicine that may stop tumor growth)—in people with high-grade brain tumors that are growing. Participants will receive these treatments before and after their planned surgery.
Rochester, MinnesotaAges 18 years+ - NCT07608003Recruiting
MRI AI model study for midline brain tumors
This study uses artificial intelligence to analyze MRI scans of midline brain tumors (gliomas) to help predict how the disease may progress and improve treatment planning. Researchers are collecting data from multiple hospitals to teach an AI system to better understand these tumors.
Changsha, HunanAges Any age
Hear when a new Oligodendroglioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Oligodendroglioma trials by city
Studies with a site in or near these metro areas.
Oligodendroglioma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for oligodendroglioma?
- Yes. Clin2 currently lists 21 recruiting oligodendroglioma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a oligodendroglioma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a oligodendroglioma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.